Lifestyle & Healthresearch summary
Tango reports 82% tumor response rate for combination therapy in advanced pancreatic cancer
The figure is lower than the 92% the company reported in June, and it comes from a larger group of patients.
This article is general information, not medical advice. Talk to a doctor or another qualified professional about your own situation.
The finding
Tango reports an 82% tumor response rate for its trial of a combination therapy in advanced pancreatic cancer, a result that matters to people living with the disease and their families [1]. The combination pairs vopimetostat with daraxonrasib [2].
CEO Malte Peters said the response rate and durability of the combination surpass any published PDAC datasets, even in front-line settings [3]. PDAC is pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer.
Why the number changed
The 82% response rate is a drop from the 92% response rate Tango reported in June, which came from fewer patients [2]. In June, the company reported data from 12 patients showing a 92% response rate and 90% progression-free survival at six months [2].
Progression-free survival is the share of patients whose cancer has not grown at a set time point. The new figure comes from a larger group, so the two numbers are not drawn from the same pool of patients [2].
Dosing results
Dose level 2, which used 250 mg vopimetostat and 600 mg daraxonrasib, was not well tolerated [2]. Three of four patients at that level experienced dose-limiting toxicities, meaning side effects serious enough to limit the dose [2].
The drug behind the combination
The FDA approved daraxonrasib, as Rasonque, for second-line pancreatic cancer [2]. In September, weeks after that approval, the agency granted Breakthrough Therapy Designation to daraxonrasib in the first-line setting [2].
What Tango plans next
Tango plans to launch a Phase 3 trial of the combination in front-line pancreatic cancer patients with MTAP deletions in the first half of 2027 [2]. Approximately 40% of patients with pancreatic cancer have an MTAP deletion [2].
The company also plans to seek FDA guidance on a possible accelerated approval path for vopimetostat plus daraxonrasib in second-line pancreatic cancer [2]. A Friday SEC filing says Tango is deprioritizing novel target discovery [2].
What it means for you
If you or a family member has pancreatic cancer, the MTAP deletion is the detail to watch, because Tango's planned Phase 3 trial is aimed at front-line patients with that deletion [2]. About 40% of patients with pancreatic cancer have one [2].
Daraxonrasib is already FDA approved, as Rasonque, for second-line pancreatic cancer [2]. The combination with vopimetostat is not approved, and Tango plans to ask the FDA about a possible accelerated approval path in the second-line setting [2].
Sources
Written from the sources above and checked twice before publishing. How we work · Report an error
![500px provided description: 1cun2491 Jpg [#summer ,#shanghai ,#lol ,#lpl ,#bruceliu]](https://thumb.wikimedia.org/wikipedia/commons/thumb/5/50/Snake_Esports_vs_Oh_My_God%2C_19_July_2015_Shanghai_%28115500173%29.jpg/1280px-Snake_Esports_vs_Oh_My_God%2C_19_July_2015_Shanghai_%28115500173%29.jpg?utm_source=commons.wikimedia.org&utm_campaign=imageinfo&utm_content=thumbnail "Photo (illustrative): Bruce Liu / Wikimedia Commons, CC BY-SA 3.0")
.jpg){kind=link}
_03.jpg){kind=link}
